QuickView for Calcium Acetate (compound)

Summary
General Info

PubChem

PubChem Compound 517040

Name:	calcium acetate
PubChem Compound ID:	517040
Molecular formula:	C₄H₆CaO₄
Molecular weight:	158.166 g/mol
Synonyms:	Acetic acid, calcium salt, hydrate

DrugBank

Identification

Name:	calcium acetate
Name (isomeric):	DB00258
Drug Type:	small molecule
Synonyms:	Gray acetate; Grey acetate; Calcium acetate hydrate; Lime pyrolignite; Calcium acetate monohydrate; Procalamine; Lime acetate; Gray acetate of lime; Acetic acid, calcium salt; Pyrolignite of lime. show more » Gray acetate; Grey acetate; Calcium acetate hydrate; Lime pyrolignite; Calcium acetate monohydrate; Procalamine; Lime acetate; Gray acetate of lime; Acetic acid, calcium salt; Pyrolignite of lime; Vinegar salts; Brown acetate; Brown acetate of lime; Calcium diacetate show less «
Brand:	PhosLo Gelcaps, Niacet calcium acetate tech, Calac, Teltozan, Sorbo-calcion, Sorbo-calcian, PhosLo
Brand name mixture:	Medi-Kool Pak(Aluminum Sulfate + Arnica + Boric Acid + Calcium Acetate + Camphor + Menthol + Methyl Salicylate + Tannic Acid), Thc Complex #66(Aconite + Barium Carbonate + Belladonna + Bryonia + Calcium Acetate + Oyster Shells + Phytolacca Decandra + Poison Ivy + Sulfur), Anti Stress(Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione ... show more » Medi-Kool Pak(Aluminum Sulfate + Arnica + Boric Acid + Calcium Acetate + Camphor + Menthol + Methyl Salicylate + Tannic Acid), Thc Complex #66(Aconite + Barium Carbonate + Belladonna + Bryonia + Calcium Acetate + Oyster Shells + Phytolacca Decandra + Poison Ivy + Sulfur), Anti Stress(Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium (Potassium Bicarbonate) + Pyridoxine Hydrochloride + Sodium Acetate + Sodium Chloride + Vitamin a + Vitamin B12 + Vitamin C + Vitamin D3 + Vitamin E), Renodoron - Tablet(Calcium Acetate + Silicon Dioxide), Mineralytes Plus(Calcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Dl-Alpha Tocopheryl Acetate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3), Thc Complex #19(Aconite + Antimony Trisulfide + Arnica Montana + Beechwood Creosote + Belladonna + Calcium Acetate + Calcium Fluoride + Calcium Phosphate (Tribasic) + Citrullus Colocynthis + Coffee + Delphinium Staphisagria + Ferrum Phosphoricum + German Chamomile + Magnesium Phosphate Dibasic + Plantago Major + Podophyllum + Silicon Dioxide), Lypholyte Multi-Electrolyte Conc Inj(Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate), Tym-Plex(Calcium Acetate + Calcium Sulfide Crude + Echinacea Angustifolia + Phosphoric Acid + Phosphorus), Parvit Ii(Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite (Vitamin K3) + Potassium (Potassium Bicarbonate) + Sodium (Sodium Acetate, Sodium Diacetate, Sodium Chloride) + Vitamin a + Vitamin B12 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Vitamin C) + Vitamin D3 + Vitamin E), Electrolyte Booster- Soluble Powder(Biotin + Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Bicarbonate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)), Vitadol Plus Soluble Powder(Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Bicarbonate + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E), Electrovite(Calcium Acetate + Calcium Chloride + Folic Acid + Magnesium Acetate + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E), Super Electrolyte - Pwr Orl(Calcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)), Electrolytes Plus(Calcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E), Jugelect Tab(Calcium Acetate + Calcium Citrate + Magnesium Acetate + Magnesium Citrate + Potassium Chloride + Sodium Chloride), Lypholyte - Liq Iv(Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate), Hyperlyte(Multi-Electrolyte Concentrate) (Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate) show less «
Category:	Antihyperphosphatemics, Chelating Agents
CAS number:	62-54-4

Pharmacology

Indication:	Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Pharmacology:	Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention lea... show more » Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine. show less «
Mechanism of Action:	Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
Absorption:	40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Route of elimination:	Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Toxicity:	Oral, rat: LD₅₀ = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Clodronate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Liotrix	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
Ciprofloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Doxycycline	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Calcium Chloride	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.

Clodronate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Liotrix	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
Ciprofloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Doxycycline	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Calcium Chloride	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
Tetracycline	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Norfloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Gemifloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Tiludronate	The divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
Demeclocycline	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Sparfloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Risedronate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate.
Nalidixic Acid	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Trientine hydrochloride	Calcium salts such as calcium acetate may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of Calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk.
Levothyroxine	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
Estramustine	Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk.
Ofloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Ibandronate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.
Calcium carbonate	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
Ceftriaxone	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
Levofloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Liothyronine	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
Alendronate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate.
Etidronic acid	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Lomefloxacin	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
Eltrombopag	Calcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.
Trovafloxacin	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction.
Minocycline	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.

show less «

Targets

Phosphate